{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:34:38Z","timestamp":1792427678554,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-026-01171-w","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:20:30Z","timestamp":1786432830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influenza A(H1N1) triggered atypical hemolytic uremic syndrome in a child with homozygous CD46 variant successfully treated with ravulizumab: a case report"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1085-4101","authenticated-orcid":false,"given":"Liliana","family":"Mazzillo Vega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8318-6266","authenticated-orcid":false,"given":"Andrea Camila","family":"Montero Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-6945","authenticated-orcid":false,"given":"Alejandro","family":"Luna Mazzillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"6","key":"1171_CR1","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.pcl.2022.07.006","volume":"69","author":"O Boyer","year":"2022","unstructured":"Boyer O, Niaudet P. Hemolytic-uremic syndrome in children. Pediatr Clin North Am. 2022;69(6):1181\u201397. https:\/\/doi.org\/10.1016\/j.pcl.2022.07.006.","journal-title":"Pediatr Clin North Am"},{"issue":"7","key":"1171_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14072527","volume":"14","author":"RG Bogdan","year":"2025","unstructured":"Bogdan RG, Anderco P, Ichim C, Cimpean AM, Todor SB, Glaja-Iliescu M, et al. Atypical hemolytic uremic syndrome: a review of complement dysregulation, genetic susceptibility and multiorgan involvement. JCM. 2025;14(7):2527. https:\/\/doi.org\/10.3390\/jcm14072527.","journal-title":"JCM"},{"issue":"4","key":"1171_CR3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40620-023-01873-9","volume":"37","author":"G Ardissino","year":"2024","unstructured":"Ardissino G, Cresseri D, Mancuso MC, Capone V, Porcaro L, Amico V, et al. Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition. J Nephrol. 2024;37(4):1017\u201326. https:\/\/doi.org\/10.1007\/s40620-023-01873-9.","journal-title":"J Nephrol"},{"issue":"8","key":"1171_CR4","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1007\/s10875-023-01547-y","volume":"43","author":"BJ Meyer","year":"2023","unstructured":"Meyer BJ, Kunz N, Seki S, Higgins R, Ghosh A, Hupfer R, et al. Immunologic and genetic contributors to CD46-dependent immune dysregulation. J Clin Immunol. 2023;43(8):1840\u201356. https:\/\/doi.org\/10.1007\/s10875-023-01547-y.","journal-title":"J Clin Immunol"},{"issue":"18","key":"1171_CR5","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","volume":"137","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021;137(18):2438\u201349. https:\/\/doi.org\/10.1182\/blood.2020009280.","journal-title":"Blood"},{"issue":"2","key":"1171_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jaci.2025.05.010","volume":"156","author":"PR Walsh","year":"2025","unstructured":"Walsh PR, Kavanagh D. Atypical hemolytic uremic syndrome. J Allergy Clin Immunol. 2025;156(2):224\u201336. https:\/\/doi.org\/10.1016\/j.jaci.2025.05.010.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1171_CR7","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","volume":"108","author":"J Caprioli","year":"2006","unstructured":"Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267\u201379. https:\/\/doi.org\/10.1182\/blood-2005-10-007252.","journal-title":"Blood"},{"issue":"11","key":"1171_CR8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrneph.2012.195","volume":"8","author":"M Noris","year":"2012","unstructured":"Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8(11):622\u201333. https:\/\/doi.org\/10.1038\/nrneph.2012.195.","journal-title":"Nat Rev Nephrol"},{"key":"1171_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/aob-22-40","volume":"8","author":"X Wu","year":"2023","unstructured":"Wu X, Liszewski MK, Java A, Atkinson JP. Atypical hemolytic uremic syndrome: genetically-based insights into pathogenesis through an analysis of the complement regulator CD46. Ann Blood. 2023;8:27\u201327. https:\/\/doi.org\/10.21037\/aob-22-40.","journal-title":"Ann Blood"},{"key":"1171_CR10","unstructured":"NM_172351.3(CD46):c.286+1G>C AND Atypical hemolytic-uremic syndrome. In: ClinVar [Internet]. Bethesda (MD): national center for biotechnology information (NCBI); 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/RCV005867075.1\/"},{"key":"1171_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/2333794X241307535","volume":"11","author":"AD Aranzazu Ceballos","year":"2024","unstructured":"Aranzazu Ceballos AD, Mar\u00eda Mart\u00ednez S\u00e1nchez L, Pamplona Sierra AP, Vergara Y\u00e1nez D, Franco Hincapi\u00e9 L, Baquero Rodriguez R. Primary thrombotic microangiopathy in pediatric patients. Glob Pediatr Health. 2024;11:2333794X241307535. https:\/\/doi.org\/10.1177\/2333794X241307535.","journal-title":"Glob Pediatr Health"},{"issue":"7","key":"1171_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13071228","volume":"13","author":"A Mocanu","year":"2023","unstructured":"Mocanu A, Bogos RA, Lazaruc TI, Cianga AL, Lupu VV, Ioniuc I, et al. Pitfalls of thrombotic microangiopathies in children: two case reports and literature review. Diagnostics. 2023;13(7):1228. https:\/\/doi.org\/10.3390\/diagnostics13071228.","journal-title":"Diagnostics"},{"issue":"01","key":"1171_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5414\/CNCS110219","volume":"9","author":"V Silecchia","year":"2021","unstructured":"Silecchia V, D\u2019Onofrio G, Valerio E, Rubin G, Vidal E, Murer L. Influenza-associated hemolytic uremic syndrome: the pathogenic role of the virus. CNCS. 2021;9(01):45\u20138. https:\/\/doi.org\/10.5414\/CNCS110219.","journal-title":"CNCS"},{"issue":"11","key":"1171_CR14","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00467-017-3783-4","volume":"33","author":"M Bitzan","year":"2018","unstructured":"Bitzan M, Zieg J. Influenza-associated thrombotic microangiopathies. Pediatr Nephrol. 2018;33(11):2009\u201325. https:\/\/doi.org\/10.1007\/s00467-017-3783-4.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"1171_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3109\/0886022X.2010.486491","volume":"32","author":"D Bento","year":"2010","unstructured":"Bento D, Mapril J, Rocha C, Marchbank KJ, Kavanagh D, Barge D, et al. Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1). Ren Fail. 2010;32(6):753\u20136. https:\/\/doi.org\/10.3109\/0886022X.2010.486491.","journal-title":"Ren Fail"},{"issue":"1","key":"1171_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5414\/CNCS111209","volume":"12","author":"N Gkiourtzis","year":"2024","unstructured":"Gkiourtzis N, Panagopoulou P, Papadopoulou-Legbelou K, Chantavaridou S, Tramma D. A pediatric case of atypical hemolytic uremic syndrome (aHUS): could any infection play a triggering role? CNCS. 2024;12(1):32\u20135. https:\/\/doi.org\/10.5414\/CNCS111209.","journal-title":"CNCS"},{"issue":"12","key":"1171_CR17","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/ccr3.3221","volume":"8","author":"BE Nelson","year":"2020","unstructured":"Nelson BE, Hong A, Iqbal F, Jana B. A unique case of hemolytic-uremic syndrome secondary to enteropathogenic E coli. Clin Case Rep. 2020;8(12):2625\u20138. https:\/\/doi.org\/10.1002\/ccr3.3221.","journal-title":"Clin Case Rep"},{"issue":"2","key":"1171_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.transci.2016.04.012","volume":"54","author":"CW Teoh","year":"2016","unstructured":"Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016;54(2):220\u201331. https:\/\/doi.org\/10.1016\/j.transci.2016.04.012.","journal-title":"Transfus Apher Sci"},{"issue":"10","key":"1171_CR19","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.mayocp.2018.08.024","volume":"93","author":"JM Thurman","year":"2018","unstructured":"Thurman JM. Complement biomarkers of hemolytic uremic syndrome: if not one thing, maybe another. Mayo Clin Proc. 2018;93(10):1337\u20139. https:\/\/doi.org\/10.1016\/j.mayocp.2018.08.024.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"1171_CR20","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00467-018-3933-3","volume":"33","author":"K Fidan","year":"2018","unstructured":"Fidan K, G\u00f6knar N, G\u00fclhan B, Melek E, Y\u0131ld\u0131r\u0131m ZY, Bask\u0131n E, et al. Extra-renal manifestations of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2018;33(8):1395\u2013403. https:\/\/doi.org\/10.1007\/s00467-018-3933-3.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"1171_CR21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jfma.2022.10.006","volume":"122","author":"MH Tseng","year":"2023","unstructured":"Tseng MH, Lin SH, Tsai JD, Wu MS, Tsai IJ, Chen YC, et al. Atypical hemolytic uremic syndrome: consensus of diagnosis and treatment in Taiwan. J Formos Med Assoc. 2023;122(5):366\u201375. https:\/\/doi.org\/10.1016\/j.jfma.2022.10.006.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"1171_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1314-1","volume":"20","author":"J Menne","year":"2019","unstructured":"Menne J, Delmas Y, Fakhouri F, Licht C, Lommel\u00e9 \u00c5, Minetti EE, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019;20(1):125. https:\/\/doi.org\/10.1186\/s12882-019-1314-1.","journal-title":"BMC Nephrol"},{"issue":"5","key":"1171_CR23","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00467-023-06120-8","volume":"39","author":"L Antonucci","year":"2024","unstructured":"Antonucci L, Thurman JM, Vivarelli M. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Pediatr Nephrol. 2024;39(5):1387\u2013404. https:\/\/doi.org\/10.1007\/s00467-023-06120-8.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"1171_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701\u201311. https:\/\/doi.org\/10.1016\/j.kint.2015.11.026.","journal-title":"Kidney Int"},{"issue":"1","key":"1171_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","volume":"100","author":"G Ariceta","year":"2021","unstructured":"Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int. 2021;100(1):225\u201337. https:\/\/doi.org\/10.1016\/j.kint.2020.10.046.","journal-title":"Kidney Int"},{"issue":"1","key":"1171_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","volume":"12","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Fila M, Prov\u00f4t F, Delmas Y, Barbet C, Ch\u00e2telet V, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. CJASN. 2017;12(1):50\u20139. https:\/\/doi.org\/10.2215\/CJN.06440616.","journal-title":"CJASN"},{"issue":"9","key":"1171_CR27","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ckj\/sfab005","volume":"14","author":"G Ariceta","year":"2021","unstructured":"Ariceta G, Fakhouri F, Sartz L, Miller B, Nikolaou V, Cohen D, et al. Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. Clin Kidney J. 2021;14(9):2075\u201384. https:\/\/doi.org\/10.1093\/ckj\/sfab005.","journal-title":"Clin Kidney J"},{"issue":"23","key":"1171_CR28","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.1182\/bloodadvances.2025017004","volume":"9","author":"A Hockman","year":"2025","unstructured":"Hockman A, Anuskiewicz S, Brennan E, Chowdhury SR, Coltoff A, Poston JN, et al. Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis. Blood Adv. 2025;9(23):6096\u2013107. https:\/\/doi.org\/10.1182\/bloodadvances.2025017004.","journal-title":"Blood Adv"},{"issue":"1","key":"1171_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","volume":"8","author":"RN Bouwmeester","year":"2023","unstructured":"Bouwmeester RN, Duineveld C, Wijnsma KL, Bemelman FJ, Van Der Heijden JW, Van Wijk JAE, et al. Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study. Kidney Int Rep. 2023;8(1):91\u2013102. https:\/\/doi.org\/10.1016\/j.ekir.2022.10.013.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"1171_CR30","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s00467-018-4091-3","volume":"34","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, Duineveld C, Wetzels JFM, Van De Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2019;34(11):2261\u201377. https:\/\/doi.org\/10.1007\/s00467-018-4091-3.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"1171_CR31","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/bloodadvances.2020003175","volume":"5","author":"S Chaturvedi","year":"2021","unstructured":"Chaturvedi S, Dhaliwal N, Hussain S, Dane K, Upreti H, Braunstein EM, et al. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv. 2021;5(5):1504\u201312. https:\/\/doi.org\/10.1182\/bloodadvances.2020003175.","journal-title":"Blood Adv"},{"issue":"1","key":"1171_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15\u201339. https:\/\/doi.org\/10.1007\/s00467-015-3076-8.","journal-title":"Pediatr Nephrol"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01171-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-026-01171-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01171-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:20:32Z","timestamp":1786432832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-026-01171-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1171"],"URL":"https:\/\/doi.org\/10.1007\/s13730-026-01171-w","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have declared that no Conflict of interest exists.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the legal guardians of the participant included in the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"131"}}